BeOne Medicines (DE:49BA)

NASDAQ:49BA

49BA

BeOne Medicines

RESEARCH TOOLSreports

BeOne Medicines (49BA) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

49BA Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

BeOne

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

49BA Stock 12 Month Forecast

Average Price Target

€342.50

▲(26.85% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is €342.50 with a high forecast of €390.59 and a low forecast of €287.12. The average price target represents a 26.85% change from the last price of €270.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"205":"€205","298":"€298","391":"€391","251.5":"€251.5","344.5":"€344.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":390.58997256,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€390.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":342.4955937794182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€342.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":287.12243016,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€287.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[205,251.5,298,344.5,391],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,240,251.5838440430769,263.1676880861538,274.7515321292308,286.3353761723077,297.9192202153846,309.5030642584615,321.0869083015384,332.6707523446154,344.2545963876923,355.8384404307692,367.42228447384616,379.006128516923,{"y":390.58997256,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,240,247.88427644457062,255.76855288914126,263.6528293337119,271.5371057782825,279.42138222285314,287.30565866742376,295.18993511199443,303.07421155656505,310.95848800113566,318.8427644457063,326.72704089027695,334.61131733484757,{"y":342.4955937794182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,240,243.62480232000001,247.24960464,250.87440696000002,254.49920928,258.1240116,261.74881392000003,265.37361624,268.99841856,272.62322088,276.24802320000003,279.87282552,283.49762784,{"y":287.12243016,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":212,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":258,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€390.59

Average Price Target€342.50

Lowest Price Target€287.12

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Schmidt

Guggenheim

€362.14

Buy

34.12%

Upside

Reiterated

06/15/26

Guggenheim Remains a Buy on BeOne Medicines (ONC)

Etzer Darout

Barclays

€352.65

Buy

30.61%

Upside

Reiterated

06/15/26

BeOne Medicines (ONC) Gets a Buy from Barclays

Yigal Nochomovitz

Citi

€390.59

Buy

44.66%

Upside

Reiterated

06/12/26

BeOne Medicines (ONC) Gets a Buy from Citi

Kalpit Patel

Wolfe Research

€293.16

Buy

8.58%

Upside

Reiterated

06/03/26

Wolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)

Yaron Werber

TD Cowen

€365.59

Buy

35.40%

Upside

Reiterated

06/02/26

TD Cowen Remains a Buy on BeOne Medicines (ONC)

Leonid Timashev

RBC Capital

€366.45→€375.93

Buy

39.23%

Upside

Assigned

06/02/26

RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX), BeOne Medicines (NASDAQ: ONC) and Autonomix Medical, Inc. (NASDAQ: AMIX)

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

06/02/26

Analysts Conflicted on These Healthcare Names: BeOne Medicines (NASDAQ: ONC), Moderna (NASDAQ: MRNA) and Danaher (NYSE: DHR)

Faisal Khurshid

Jefferies

€250.05→€287.12

Hold

6.34%

Upside

Reiterated

05/21/26

Jefferies Reaffirms Their Hold Rating on BeOne Medicines (ONC)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

€313.85→€316.44

Buy

17.20%

Upside

Reiterated

05/15/26

Leerink Partners Keeps Their Buy Rating on BeOne Medicines (ONC)

Jill Wu

CMB International Securities

€338.36

Buy

25.32%

Upside

Reiterated

05/07/26

Analysts Are Bullish on These Healthcare Stocks: BeOne Medicines (ONC), Alector (ALEC)

Sean Laaman

Morgan Stanley

€335.41→€340.58

Buy

26.14%

Upside

Reiterated

05/07/26

BeOne Medicines price target raised to $395 from $389 at Morgan StanleyBeOne Medicines price target raised to $395 from $389 at Morgan Stanley

Yanan Zhu

Wells Fargo

€344.89

Buy

27.74%

Upside

Reiterated

05/07/26

BeOne Medicines (ONC) Gets a Buy from Wells Fargo

Rebecca Liang

Bernstein

€355.24

Buy

31.57%

Upside

Reiterated

03/18/26

Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)

David Li

Bank of America Securities

€335.41→€346.79

Buy

28.44%

Upside

Reiterated

11/07/25

BeOne Medicines (ONC) Receives a Buy from Bank of America Securities

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Schmidt

Guggenheim

€362.14

Buy

34.12%

Upside

Reiterated

06/15/26

Guggenheim Remains a Buy on BeOne Medicines (ONC)

Etzer Darout

Barclays

€352.65

Buy

30.61%

Upside

Reiterated

06/15/26

BeOne Medicines (ONC) Gets a Buy from Barclays

Yigal Nochomovitz

Citi

€390.59

Buy

44.66%

Upside

Reiterated

06/12/26

BeOne Medicines (ONC) Gets a Buy from Citi

Kalpit Patel

Wolfe Research

€293.16

Buy

8.58%

Upside

Reiterated

06/03/26

Wolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)

Yaron Werber

TD Cowen

€365.59

Buy

35.40%

Upside

Reiterated

06/02/26

TD Cowen Remains a Buy on BeOne Medicines (ONC)

Leonid Timashev

RBC Capital

€366.45→€375.93

Buy

39.23%

Upside

Assigned

06/02/26

RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX), BeOne Medicines (NASDAQ: ONC) and Autonomix Medical, Inc. (NASDAQ: AMIX)

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

06/02/26

Analysts Conflicted on These Healthcare Names: BeOne Medicines (NASDAQ: ONC), Moderna (NASDAQ: MRNA) and Danaher (NYSE: DHR)

Faisal Khurshid

Jefferies

€250.05→€287.12

Hold

6.34%

Upside

Reiterated

05/21/26

Jefferies Reaffirms Their Hold Rating on BeOne Medicines (ONC)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

€313.85→€316.44

Buy

17.20%

Upside

Reiterated

05/15/26

Leerink Partners Keeps Their Buy Rating on BeOne Medicines (ONC)

Jill Wu

CMB International Securities

€338.36

Buy

25.32%

Upside

Reiterated

05/07/26

Analysts Are Bullish on These Healthcare Stocks: BeOne Medicines (ONC), Alector (ALEC)

Sean Laaman

Morgan Stanley

€335.41→€340.58

Buy

26.14%

Upside

Reiterated

05/07/26

BeOne Medicines price target raised to $395 from $389 at Morgan StanleyBeOne Medicines price target raised to $395 from $389 at Morgan Stanley

Yanan Zhu

Wells Fargo

€344.89

Buy

27.74%

Upside

Reiterated

05/07/26

BeOne Medicines (ONC) Gets a Buy from Wells Fargo

Rebecca Liang

Bernstein

€355.24

Buy

31.57%

Upside

Reiterated

03/18/26

Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)

David Li

Bank of America Securities

€335.41→€346.79

Buy

28.44%

Upside

Reiterated

11/07/25

BeOne Medicines (ONC) Receives a Buy from Bank of America Securities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines

3 Months

Andrew BerensLeerink Partners

Success Rate

12/21 ratings generated profit

Average Return

+7.57%

Copying Andrew Berens's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +7.57% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

27/36 ratings generated profit

Average Return

+34.19%

Copying Yaron Werber's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +34.19% per trade.

2 Years

Jill WuCMB International Securities

Success Rate

13/18 ratings generated profit

Average Return

+28.86%

Copying Jill Wu's trades and holding each position for 2 Years would result in 72.22% of your transactions generating a profit, with an average return of +28.86% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

49BA Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 49BA has received 28 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 49BA average Analyst price target in the past 3 months is 342.50.

Each month's total comprises the sum of three months' worth of ratings.

49BA Financial Forecast

49BA Earnings Forecast

Next quarter’s earnings estimate for 49BA is €1.44 with a range of €0.94 to €3.09. The previous quarter’s EPS was €1.71. 49BA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 49BA has Performed in-line its overall industry.

49BA Sales Forecast

Next quarter’s sales forecast for 49BA is €1.39B with a range of €1.34B to €1.45B. The previous quarter’s sales results were €1.32B. 49BA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 49BA has Performed in-line its overall industry.

49BA Stock Forecast FAQ

What is DE:49BA’s average 12-month price target, according to analysts?

Based on analyst ratings, BeOne Medicines’s 12-month average price target is 342.50.

What is DE:49BA’s upside potential, based on the analysts’ average price target?

BeOne Medicines has 26.85% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BeOne Medicines a Buy, Sell or Hold?

BeOne Medicines has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is BeOne Medicines’s share price target?

The average share price target for BeOne Medicines is 342.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €390.59 ,and the lowest forecast is €287.12. The average share price target represents 26.85% Increase from the current price of €270.

What do analysts say about BeOne Medicines?

BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of BeOne Medicines?

To buy shares of DE:49BA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

BeOne Medicines (49BA) Stock Forecast & Price Target

49BA Analyst Ratings

49BA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BeOne Medicines

49BA Analyst Recommendation Trends

49BA Financial Forecast

49BA Earnings Forecast

49BA Sales Forecast

49BA Stock Forecast FAQ

Detailed List of Analyst Forecasts